A process for reducing solvent contents in drug-containing polymeric compositions may be utilized to reduce the solvent content in implantable medical device wherein the compositions are in reservoirs. Specifically, the solvent contents in the drug-containing polymeric compositions are first reduced by one or more conventional drying methods, to a range from about 0.5 weight percent to about 10 weight percent of the total weight of the polymeric composition. Subsequently, the drug-containing polymeric compositions are further treated by a low temperature drying method for further reduction of the solvent content.

Extraction of solvents from drug containing polymer reservoirs

The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.

Ocular hypotensive agents

The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

Chimeric antigen receptor and methods of use thereof

A coated medical device, such as a stent, that elutes a taxane agent in a controlled manner is provided. In one embodiment, the taxane agent is paclitaxel and at least a portion of the paclitaxel is present in a dihydrate solid form. The medical device may be coated with a layer including a taxane agent and a layer of bioabsorbable elastomer over the layer including the taxane agent. Methods of manufacturing and using the coated medical device are also provided.

Implantable medical device coatings with biodegradable elastomer and releasable taxane agent

Medical devices may be utilized for local and regional therapeutic agent delivery. These therapeutic agents or compounds may reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including restenosis, vulnerable plaque, and atherosclerosis in type 2 diabetic patients. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned.

Device for local and/or regional delivery employing liquid formulations of therapeutic agents

The present invention provides a method of preparing .alpha.,.beta.-unsaturated ketolactones which are useful in the production of prostaglandins having one or more halogen substituent(s) at position 16 or 17 in high yield, in which, a dimethyl (2-oxoalkyl) phosphonate having one or more halogen substituents (as a starting material) is reacted with a bicyclolactone aldehyde in the presence of an alkali metal hydride and a zinc compound.

Method of producing alpha, beta unsaturated ketolactones

PURPOSE:To obtain an intraocular tension lowering agent effective for treating glaucoma free from side effects comprising a 13,14-dihydro-15-keto-prostaglandin as an active ingredient. CONSTITUTION:An intraocular tension lowering agent comprising a 13,14- dihydro-15-keto-prostaglandin, especially one containing an alkyl ester (especially 1-4C alkyl ester) as the carboxyl group as the alpha-chain end or one of 20-alkyl derivative prepared by replacing (extension of alpha-chain) carbon at the-20 position with an alkyl group (especially 1-4C alkyl) as an active ingredient. The compound develops strongly lowering action on intraocular tension without exhibiting transient rise in intraocular tension shown by prostaglandins, has no side effects such as strong afflux of conjunctiva and iris, closing of eye, tearing, etc., and characteristic actions of prostaglandins on intestine, air tubes and bronchial tubes are not also observed.

Intraocular tension lowering agent

PURPOSE:To obtain a medicinal preparation which includes 15-dehydroxy- prostaglandin as an active ingredient and is useful as an allergic disease-treating agent, inflammatory disease-treating agent, antihistamic agent and a bronchodilator because it has the antagonistic action on histamine. CONSTITUTION:15-Dehydroxy-prostaglandin of the formula [X, Y are H, OH, a halogen, a lower alkyl which may be substituted, oxo, where at least one of X, Y is a group other than H; A is CH2OH, COOH; R1 is the residue of a divalent aliphatic hydrocarbon; R2 is the residue of an aliphatic hydrocarbon which may be substituted; the five-membered ring may have double bonds] is used as an active ingredient, combined with a diluent, a lubricant, a disintegrator, a stabilizer and the like to prepare eye drop, nasal drop, tablets, troche, capsules, pills, powder, granules or injection solution whereby the objective biochemical antagonist and disease-treating agent is obtained as an allergic diseasetreating agent, inflammatory disease-treating agent, an antihistamic agent or a bronchodilator.

Biological antagonist and disease-treating preparation

This invention provides a hypersphyxia-causing composition containing 15-keto-PGEs esters separated from any substantial activity such as decrease of blood pressure. The present invention provides a hypersphyxia-causing composition effective to recovery of blood pressure, and heart rate in e.g. hemorrhage shock, or hyperventilation, which comprises 15-keto-PGEs esters.

Hypersphyxia causing composition.

PURPOSE:To obtain new 15-keto-prostaglandins having a prostaglandin agent useful for preventing and treating cataract. CONSTITUTION:A compound, e.g. isopropyl (Z)-9-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3- oxodecyl)cyclopentyl]-7-nonenoate expressed by formula I [L and M are H, hydroxy, lower alkyl, etc., provided that at least one of L and M is a group other than H and the 5-membered rind may have at least one double bond; X1 and X2 are H, halogen, etc.; Q is CH2CH2CH2, CHCHCH2, etc.; Y is CH2CH2, CHCH, etc.; Z is CH2CH2 or CHCH; R1 is H, lower alkyl, etc.; R2 is single bond or lower alkylene; R3 is (halogen-substituted) lower alkyl, etc.]. For example, a compound expressed by formula II (P1 is protecting group) is reacted with a ylide obtained from (6-carboxyhexyl)triphenylphosphonium bromide and the resultant compound is then esterified to afford a compound expressed by formula III. The protecting groups are further removed to provide the objective compound.

Tomio Oda

Papers

Method of producing alpha, beta unsaturated ketolactones

Intraocular tension lowering agent

Biological antagonist and disease-treating preparation

Hypersphyxia causing composition.

New 15-keto-prostaglandins